Arab Board Oncology Part 1 common mistakes
Arab Board Oncology Part 1 · Understand the traps and how to avoid them.
When a statistics vignette gives a p value below 0.05, the candidate immediately labels the intervention as proven and clinically superior without checking effect size, confidence interval width, power, or multiplicity.
It happens because many candidates reduce biostatistics to a threshold rule and ignore that statistical significance is not the same as clinical importance or validity.
What to do instead
For every trial or study question, write out the population, intervention, comparator, outcome, design, primary endpoint, effect size with confidence interval, alpha and multiplicity, then decide separately whether the result is valid, statistically significant, and clinically meaningful.
The candidate calculates or interprets screening test performance by mixing up incidence, prevalence, sensitivity, specificity, and positive predictive value, or explains a screening benefit without naming lead-time or length bias.
It happens because screening concepts are learned as isolated definitions rather than as a temporal and population framework, and exam stems deliberately change prevalence or follow-up time.
What to do instead
Draw a 2x2 table for every screening calculation, state the prevalence used, calculate sensitivity, specificity and predictive values, and separately identify the bias that could explain improved survival without reduced mortality.
In a febrile neutropenia, suspected malignant spinal cord compression, or tumour lysis syndrome scenario, the candidate orders further confirmatory tests or waits for imaging results before starting empiric antibiotics, corticosteroids, or urgent hydration and urate-lowering treatment.
It happens because candidates apply general diagnostic caution and forget that these oncologic emergencies are time-critical and that treatment delay worsens outcome.
What to do instead
Memorise emergency action bundles: cultures then immediate broad-spectrum antibiotics for febrile neutropenia, urgent corticosteroids and imaging for cord compression, and immediate hydration plus monitoring for tumour lysis syndrome; state the first action explicitly in the answer.
The candidate selects a systemic therapy regimen from the tumour name alone and does not adjust for renal or hepatic function, prior cumulative anthracycline dose, drug interactions, premedication requirements, or growth factor prophylaxis.
It happens because regimens are memorised as acronyms and the safety details are studied separately from the indication, so the vignette's organ function or prior treatment is overlooked.
What to do instead
For each regimen, build a drug-specific safety checklist covering organ adjustment, cumulative dose limits, infusion reactions, emetogenicity, interactions, and monitoring, and apply the checklist to the scenario before choosing the regimen.
The candidate compares radiotherapy regimens by total dose alone and concludes that a higher total dose is always more effective, without calculating biologically effective dose or considering dose per fraction, alpha/beta ratio, and normal tissue tolerance.
It happens because total dose is the most visible number and fractionation biology is often memorised as isolated definitions rather than applied quantitatively.
What to do instead
Convert each regimen to biologically effective dose or equivalent dose in 2 Gy fractions for both tumour and late-responding normal tissue, then compare tumour control probability against normal tissue constraints before answering.
The candidate manages immune-related adverse events like conventional chemotherapy toxicity, for example continuing a checkpoint inhibitor through grade 3 colitis or withholding corticosteroids because of fears about immunosuppression.
It happens because immunotherapy toxicity is still mentally grouped with cytotoxic adverse effects, and the distinctive mechanism and grading rules for immune-related events are not recalled under time pressure.
What to do instead
Grade the immune-related adverse event explicitly, state whether to hold or permanently stop the checkpoint inhibitor, and start corticosteroids early for most grade 2 or higher events except specified endocrine toxicities; distinguish endocrine replacement from immunosuppressive treatment.
The candidate uses an elevated tumour marker alone to diagnose cancer or recurrence, or treats a variant of uncertain significance as a pathogenic mutation requiring a targeted drug or family screening.
It happens because tumour markers and molecular reports are overinterpreted as definitive tests, and variant classification is confused with simply detecting a mutation.
What to do instead
Use tumour markers only as adjuncts in the correct clinical context and require histologic or imaging confirmation; classify molecular variants as pathogenic, likely pathogenic, uncertain, or benign before making treatment or family screening decisions.
The candidate reads a pathology report only for the diagnostic line and ignores grade, margin status, lymphovascular invasion, perineural invasion, and the immunohistochemical or molecular results that determine prognosis and adjuvant treatment.
It happens because the diagnosis is the most salient piece of information and the report is treated as a label rather than as a structured prognostic document.
What to do instead
Use a structured pathology checklist for every case: diagnosis, grade, margins, lymphovascular and perineural invasion, node count, immunohistochemistry, and molecular results, then link each positive finding to staging or treatment.
The candidate assigns a stage from a memorised table without distinguishing clinical, pathological, and post-neoadjuvant staging, and ignores unknown or equivocal descriptors such as cN versus pN or yp stage.
It happens because familiar tumour-stage pairs are pattern-matched and the TNM prefix rules and unknown descriptors are treated as details rather than as part of the stage definition.
What to do instead
Before assigning stage, state the TNM version and prefix, confirm whether the data are clinical, pathological, or post-neoadjuvant, resolve unknown descriptors explicitly, and then apply the stage grouping rules.
In an ethics, consent, or breaking-bad-news scenario, the candidate answers with what the clinician should disclose or decide but does not assess the patient's capacity, understanding, confidentiality, or substituted judgment.
It happens because candidates focus on the biomedical correct action and treat communication and professionalism as common sense rather than as assessable clinical skills.
What to do instead
Use a structured framework: assess capacity, obtain informed consent, use teach-back to confirm understanding, respect confidentiality and exceptions, and distinguish patient wishes from family requests unless the patient lacks capacity.